Search Results
Jun 25, 2026, 13:58 ET Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-tbrg-ogn-mdv-obtaining-fair-deals-for-their-shareholders-302810921.htmlSOURCE
More news about: Halper Sadeh LLP
May 14, 2026, 17:25 ET Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-xoma-ogn-vre-obtaining-fair-deals-for-their-shareholders-302772798.htmlSOURCE
More news about: Halper Sadeh LLP
May 06, 2026, 14:27 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX
OGN) related to its sale to Sun Pharmaceuticals Industries Limited. Under the terms of the proposed transaction, Organon shareholders will receive
More news about: Monteverde & Associates PC
May 04, 2026, 14:55 ET Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-ogn-tbrg-cycn-obtaining-fair-deals-for-their-shareholders-302761532.htmlSOURCE
More news about: Halper Sadeh LLP
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous
More news about: Henlius
Apr 27, 2026, 11:24 ET Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-ogn-rmax-xoma-reax-obtaining-fair-deals-for-their-shareholders-302754264.htmlSOURCE
More news about: Halper Sadeh LLP
Apr 27, 2026, 02:23 ET Shareholder Alert: Ademi LLP investigates whether Organon & Co. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, April 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Organon (NYSE: OGN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sun Pharma.
More news about: Ademi LLP
Mar 30, 2026, 03:15 ET Organon ने 2026 Her Health Grants के साथ एशिया प्रशांत क्षेत्र में Women's Health की प्रगति को गति प्रदान की
कार्यक्रम और गतिविधियाँ संबंधित संगठनों द्वारा स्वतंत्र रूप से तैयार और कार्यान्वित की जाती हैं।Organon का परिचयOrganon (NYSE: OGN) एक वैश्विक स्वास्थ्य सेवा कंपनी है जिसका मिशन स्वस्थ जीवन के लिए प्रभावी दवाएं और समाधान प्रदान करना है। महिलाओं के स्वास्थ्य और सामान्य चिकित्सा के
More news about: Organon
Mar 29, 2026, 18:50 ET Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
by Her Health grants remain independently designed and implemented by the organizations in question.About Organon[Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products
More news about: Organon
Mar 16, 2026, 16:05 ET Alger Russell Innovation Index Updates for First Quarter 2026
Organon & Co.OGNFor additional information, please visit www.lseg.com.Unlock
More news about: Alger
Feb 16, 2026, 17:31 ET Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
(NASDAQ: NKTR), Apogee Therapeutics (NASDAQ: APGE), Roche (SWX: ROG), Genentech, Eli Lilly and Company (NYSE: LLY), Almirall (BME: ALM), Organon (NYSE: OGN), Torii Pharmaceutical, Chugai Pharmaceutical (TYO: 4519), Galderma, Maruho, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), Regeneron Pharmaceuticals (NASDAQ:
More news about: DelveInsight Business Research, LLP
Nov 07, 2025, 22:47 ET Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (
More news about: Kahn Swick & Foti, LLC